featured
Stereotactic Ablative Radiotherapy ± Immunotherapy for Early-Stage Treatment-Naïve or Isolated Lung Parenchymal Recurrent Node-Negative NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial
Lancet 2023 Jul 18;[EPub Ahead of Print], JY Chang, SH Lin, W Dong, Z Liao, SJ Gandhi, CM Gay, J Zhang, SG Chun, YY Elamin, FV Fossella, G Blumenschein, T Cascone, X Le, JV Pozadzides, A Tsao, V Verma, JW Welsh, AB Chen, M Altan, RJ Mehran, AA Vaporciyan, SG Swisher, PA Balter, J Fujimoto, II Wistuba, L Feng, JJ Lee, JV HeymachFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.